Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Start Date
10/6/2014
Completion Date
1/30/2032
Summary
This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
Fludarabine
Cyclophosphamide
Total Body Irradiation
Hematopoietic stem cell infusion
Conditions
Locations
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota 55455
United States